通过两项3期双盲试验的汇总分析，按严重程度衡量替加环素与利奈唑胺治疗急性细菌性皮肤及皮肤结构感染的临床反应
Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.
作者信息
Sandison Taylor, De Anda Carisa, Fang Edward, Das Anita F, Prokocimer Philippe
机构信息
Merck & Co., Inc., Kenilworth, New Jersey, USA.
Merck & Co., Inc., Kenilworth, New Jersey, USA
出版信息
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02687-16. Print 2017 May.
Abstract
Tedizolid phosphate is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In a pooled analysis of 1,333 ABSSSI patients from the ESTABLISH clinical trials, treatment with tedizolid or linezolid demonstrated similar early and posttherapy clinical responses in nonsevere and severe disease, irrespective of the parameters used to measure ABSSSI severity. Shorter 6-day treatment of ABSSSI, including those that were severe, with tedizolid phosphate demonstrated efficacy comparable to that of 10-day treatment with linezolid. (The ESTABLISH studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01170221 and NCT01421511.).
摘要
磷酸泰地唑胺已被批准用于治疗急性细菌性皮肤及皮肤结构感染（ABSSSI）。在一项对来自ESTABLISH临床试验的1333例ABSSSI患者的汇总分析中，无论用于衡量ABSSSI严重程度的参数如何，使用泰地唑胺或利奈唑胺治疗在非重症和重症疾病中均显示出相似的早期和治疗后临床反应。使用磷酸泰地唑胺对ABSSSI进行为期6天的较短疗程治疗，包括重症患者，其疗效与使用利奈唑胺进行10天疗程治疗的疗效相当。（本文讨论的ESTABLISH研究已在ClinicalTrials.gov上注册，标识符为NCT01170221和NCT01421511。）
相似文献
1
Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.
Antimicrob Agents Chemother. 2017 Apr 24;61(5). doi: 10.1128/AAC.02687-16. Print 2017 May.
2
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.
3
Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
Medicine (Baltimore). 2017 Dec;96(52):e9163. doi: 10.1097/MD.0000000000009163.
4
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.02252-18. Print 2019 Jul.
5
Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections.
J Am Podiatr Med Assoc. 2017 Jul;107(4):264-271. doi: 10.7547/15-218. Epub 2016 Aug 17.
6
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24.
7
Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.
Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783.
8
Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
BMC Infect Dis. 2017 Jan 7;17(1):39. doi: 10.1186/s12879-016-2100-3.
9
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
10
Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22.
引用本文的文献
1
Pharmacokinetics and Pharmacodynamics of Tedizolid.
Clin Pharmacokinet. 2022 Apr;61(4):489-503. doi: 10.1007/s40262-021-01099-7. Epub 2022 Feb 7.
2
Novel Antifungal Agents and Their Activity against Species.
J Fungi (Basel). 2020 Oct 9;6(4):213. doi: 10.3390/jof6040213.
3
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.
Adv Sci (Weinh). 2019 Dec 5;7(1):1901872. doi: 10.1002/advs.201901872. eCollection 2020 Jan.
4
Tedizolid Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection: A Systematic Review and Meta-Analysis.
Antibiotics (Basel). 2019 Sep 4;8(3):137. doi: 10.3390/antibiotics8030137.
5
Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy.
Core Evid. 2019 Jul 5;14:31-40. doi: 10.2147/CE.S187499. eCollection 2019.
6
Treatment Duration and Associated Outcomes for Skin and Soft Tissue Infections in Patients With Obesity or Heart Failure.
Open Forum Infect Dis. 2019 May 7;6(6):ofz217. doi: 10.1093/ofid/ofz217. eCollection 2019 Jun.
7
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.02252-18. Print 2019 Jul.
8
Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series.
Infect Dis Ther. 2018 Sep;7(3):387-399. doi: 10.1007/s40121-018-0207-0. Epub 2018 Jul 12.
9
Treatment of severe skin and soft tissue infections: a review.
Curr Opin Infect Dis. 2018 Apr;31(2):113-119. doi: 10.1097/QCO.0000000000000431.
本文引用的文献
1
Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients.
BMC Infect Dis. 2016 Nov 29;16(1):721. doi: 10.1186/s12879-016-2067-0.
2
Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.
Clin Infect Dis. 2016 May 15;62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13.
3
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
4
FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
Clin Infect Dis. 2014 Jan;58 Suppl 1:S4-9. doi: 10.1093/cid/cit612.
5
Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines.
J Emerg Med. 2013 Jun;44(6):e397-412. doi: 10.1016/j.jemermed.2012.11.050. Epub 2013 Mar 5.
6
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.
7
New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
Clin Infect Dis. 2011 Jun;52 Suppl 7:S469-76. doi: 10.1093/cid/cir162.
8
Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
Antimicrob Agents Chemother. 2010 May;54(5):2063-9. doi: 10.1128/AAC.01569-09. Epub 2010 Mar 15.
9
In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
Antimicrob Agents Chemother. 2009 Aug;53(8):3236-9. doi: 10.1128/AAC.00228-09. Epub 2009 Jun 15.
10
Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis.
Arch Intern Med. 2004;164(15):1669-74. doi: 10.1001/archinte.164.15.1669.
Zotero 插件